Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...
Microbiomes Market To Grow By USD 1.13 Billion (2024-2028), Driven By Rising Disease Prevalence AI Impact On Market Trends - Technavio
The Microbiomes Market is experiencing significant growth due to the increasing research and development in the field of ...
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
Highlights:New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum ...
Immuron Announces Travelan® Clinical Trial Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...
Monthly Prescribing Reference5d
C. Difficile Prevention Therapy Zinplava Discontinued
Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.
The American Journal of Managed Care5d
Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...
healthday5d
Fecal Transplants May Help People Who Have Diabetes, Gut Issues, Study Says
A fecal transplant could help people whose type 1 diabetes has fouled up their digestive system.Swallowing a handful o ...